NEW YORK, July 21, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer. The company is in its development stage with one approved treatment. The two most advanced assets of the company are Cabozantinib, and Cobimetinib. Exelixis has five Phase III trials for various cancer treatments using Cabozantinib and Cobimetinib. On top of those, the company has numerous strategic partnerships with other drug companies, and multiple treatments in Phase II trials. Exelixis has a huge pipeline of potential uses for its treatments.
On July 20, Exelixis announced its Cabozantinib drug showed a promising 42% reduction in the risk of disease progression or death. The announcement further touted "the most commonly utilized therapies have demonstrated a uniformly modest progression-free survival benefit". The drug is already approved for the treatment of medullary thyroid cancer, but that pulls in just $25 million in revenue annually due to the relative scarcity of the disease.
An analyst brief with an analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.